272 related articles for article (PubMed ID: 22961061)
1. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies.
Kalff A; Spencer A
Blood Cancer J; 2012 Sep; 2(9):e89. PubMed ID: 22961061
[TBL] [Abstract][Full Text] [Related]
2. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.
Richelda R; Ronchetti D; Baldini L; Cro L; Viggiano L; Marzella R; Rocchi M; Otsuki T; Lombardi L; Maiolo AT; Neri A
Blood; 1997 Nov; 90(10):4062-70. PubMed ID: 9354676
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy of multiple myeloma.
Dolloff NG; Talamo G
Adv Exp Med Biol; 2013; 779():197-221. PubMed ID: 23288641
[TBL] [Abstract][Full Text] [Related]
4. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance.
Pollett JB; Trudel S; Stern D; Li ZH; Stewart AK
Blood; 2002 Nov; 100(10):3819-21. PubMed ID: 12393593
[TBL] [Abstract][Full Text] [Related]
6. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.
Finelli P; Fabris S; Zagano S; Baldini L; Intini D; Nobili L; Lombardi L; Maiolo AT; Neri A
Blood; 1999 Jul; 94(2):724-32. PubMed ID: 10397739
[TBL] [Abstract][Full Text] [Related]
7. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
[TBL] [Abstract][Full Text] [Related]
8. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma.
Chesi M; Kuehl WM; Bergsagel PL
Ann Oncol; 2000; 11 Suppl 1():131-5. PubMed ID: 10707795
[TBL] [Abstract][Full Text] [Related]
9. A molecular study of the t(4;14) in multiple myeloma.
Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
[TBL] [Abstract][Full Text] [Related]
10. Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF.
Takimoto M; Ogawa K; Kato Y; Saito T; Suzuki T; Irei M; Shibuya Y; Suzuki Y; Kato M; Inoue Y; Takahashi M; Sugimori H; Miura I
Int J Hematol; 2008 Apr; 87(3):260-5. PubMed ID: 18274833
[TBL] [Abstract][Full Text] [Related]
11. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
[TBL] [Abstract][Full Text] [Related]
12. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
[TBL] [Abstract][Full Text] [Related]
13. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma.
Inagaki A; Tajima E; Uranishi M; Totani H; Asao Y; Ogura H; Masaki A; Yoshida T; Mori F; Ito A; Yano H; Ri M; Kayukawa S; Kataoka T; Kusumoto S; Ishida T; Hayami Y; Hanamura I; Komatsu H; Inagaki H; Matsuda Y; Ueda R; Iida S
Leuk Res; 2013 Dec; 37(12):1648-55. PubMed ID: 24210217
[TBL] [Abstract][Full Text] [Related]
14. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
Ho PJ; Brown RD; Spencer A; Jeffels M; Daniher D; Gibson J; Joshua DE
Leuk Lymphoma; 2012 Sep; 53(9):1728-34. PubMed ID: 22329352
[TBL] [Abstract][Full Text] [Related]
16. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
[TBL] [Abstract][Full Text] [Related]
17. Chromosomal and genetic abnormalities in myeloma.
Joy Ho P
Clin Lab Haematol; 2002 Oct; 24(5):259-69. PubMed ID: 12358886
[TBL] [Abstract][Full Text] [Related]
18. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies.
Nakazawa N; Nishida K; Tamura A; Kobayashi M; Iwai T; Horiike S; Nishigaki H; Otsuki T; Tomiyama Y; Fujii H; Kashima K; Taniwaki M
Cancer Genet Cytogenet; 2000 Mar; 117(2):89-96. PubMed ID: 10704676
[TBL] [Abstract][Full Text] [Related]
19. FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4.
Martin LD; Harizanova J; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2016 Dec; 55(12):962-974. PubMed ID: 27509849
[TBL] [Abstract][Full Text] [Related]
20. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
Plowright EE; Li Z; Bergsagel PL; Chesi M; Barber DL; Branch DR; Hawley RG; Stewart AK
Blood; 2000 Feb; 95(3):992-8. PubMed ID: 10648414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
